Study details
Enrolling now
CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)
Baylor College of Medicine
NCT IDNCT02917083ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1
Target enrollment
60
Study length
about 23 years
Ages
12–75
Locations
2 sites in TX
What this study is about
This trial is testing a new treatment called CD30 CAR T cells for people with lymphoma that has returned after other treatments. The goal is to see if these modified T cells can better kill cancer cells and improve outcomes.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take CAR T Cells
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
All receive treatment
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Drug classes
cell therapy (Engineered T-cells that target specific cancer antigens)
Endpoints
Primary: Number of Patients with Dose-Limiting Toxicities (DLT)
Secondary: Overall Response Rate
Body systems
Oncology